BioSpace News Archive

Business

Medivir Announces Departure of Chief Medical Officer

Medivir AB announced that John Öhd, Chief Medical Officer at Medivir, has decided to leave the company.

March 14, 2018
·
1 min read
Business

Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors

Ardelyx, Inc. reported pipeline highlights and financial results for the fourth quarter and full-year ended December 31, 2017.

March 14, 2018
·
7 min read
Business

Corindus Reports Fourth Quarter and Full Year 2017 Results

Corindus Vascular Robotics Inc. reported financial results for its fourth quarter and year ended December 31, 2017.

March 14, 2018
·
3 min read
Business

NantHealth Reports 2017 Fourth-Quarter and Full-Year Financial Results

NantHealth, Inc. reported financial results for its fourth quarter and full year ended December 31, 2017.

March 14, 2018
·
7 min read
WallachBeth Capital, LLC Acts as the Sole Placement Agent for SmartZyme’s Ongoing Series B-1 Offering

WallachBeth Capital, a leading provider of institutional execution services, is acting as the sole placement agent for SmartZyme BioPharma’s Series B-1 preferred-stock round.

March 14, 2018
·
1 min read
Business

BIOLASE Reports 2017 Fourth Quarter And Full-Year Results

Biolase, Inc. reported its financial results for its fourth quarter and year ended December 31, 2017.

March 14, 2018
·
8 min read
Business

Quanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017

Quanterix Corporation reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously announced in January 2018.

March 14, 2018
·
4 min read
Biotech Bay

Arcus Biosciences Announces Pricing of Initial Public Offering

Arcus Biosciences announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15.00 per share for total gross proceeds of $120,000,000.

March 14, 2018
·
1 min read
Drug Development

OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact

OxThera AB announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact.

March 14, 2018
·
1 min read
BioMidwest

Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract

Bio-Techne has released MimEX™ GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface.

March 14, 2018
·
3 min read